Drug Profile
Encapsulated gonorrhoea vaccine - Intravacc/Therapyx
Alternative Names: Avacc 11®; GVAX-12; NGoXIM™Latest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator TherapyX
- Class Bacterial vaccines; Interleukins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Gonorrhoea
Most Recent Events
- 01 Apr 2024 Intravacc plans phase I trial the prevention of Gonorrhoea (Intranasal, Controlled release) in 2025
- 29 Mar 2024 Encapsulated gonorrhoea vaccine is still in preclinical development in Gonorrhoea(Prevention) in USA (Intranasal, Controlled release)
- 29 Mar 2024 Encapsulated gonorrhoea vaccine - Intravacc/Therapyx is available for licensing as of 29 Mar 2024. https://www.intravacc.nl/fileadmin/01-Website/Downloads/Vaccsheet/Avacc11_Gonorrhea_0923_LR.pdf